Tag Archives: NASDAQ:AGIO

Canaccord Genuity Sticks to Their Buy Rating for Agios Pharma (AGIO)

In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Agios Pharma (AGIO – Research Report), with a price target of $70.00. The company’s shares closed last Friday at $35.87. According to TipRanks.com, Newman is

Agios Pharma (AGIO) Gets a Buy Rating from Cantor Fitzgerald

In a report released today, Alethia Young from Cantor Fitzgerald maintained a Buy rating on Agios Pharma (AGIO – Research Report), with a price target of $72.00. The company’s shares closed last Friday at $45.50. According to TipRanks.com, Young is

Analysts Conflicted on These Healthcare Names: Agios Pharma (NASDAQ: AGIO) and Cryolife (NYSE: CRY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Agios Pharma (AGIO – Research Report) and Cryolife (CRY – Research Report). Agios Pharma (AGIO) Canaccord Genuity analyst John Newman maintained a Buy

Oppenheimer Sticks to Its Hold Rating for Agios Pharma (AGIO)

In a report released yesterday, Mark Breidenbach from Oppenheimer maintained a Hold rating on Agios Pharma (AGIO – Research Report). The company’s shares closed last Friday at $47.14. According to TipRanks.com, Breidenbach is a 4-star analyst with an average return

Agios Pharma (AGIO) Gets a Buy Rating from Canaccord Genuity

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Agios Pharma (AGIO – Research Report), with a price target of $72.00. The company’s shares closed last Thursday at $41.14. According to TipRanks.com, Newman is

Oppenheimer Maintains Their Hold Rating on Agios Pharma (AGIO)

Oppenheimer analyst Mark Breidenbach maintained a Hold rating on Agios Pharma (AGIO – Research Report) today. The company’s shares closed last Thursday at $41.14. According to TipRanks.com, Breidenbach is a 5-star analyst with an average return of 8.9% and a